CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco.
瑞士楚格和波士頓，2025年1月8日（環球新聞）—— CRISPR Therapeutics（納斯達克：CRSP）是一家專注於爲嚴重疾病創造變革性基因藥物的生物醫藥公司，今天宣佈其高級管理團隊的成員將在2025年1月14日星期二下午2:15（太平洋時間）在舊金山的第43屆摩根大通醫療健康大會上進行演講。
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at . A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
會議的現場網絡直播將可以在公司網站投資者部分的 "活動與演示 "頁面上找到。演示後的14天內，將在公司網站上存檔該網絡直播的回放。
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that celebrated the historic approval of the first-ever CRISPR-based therapy in 2023 and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia, and beginning in late 2023, CASGEVY (exagamglogene autotemcel [exa-cel]) was approved in some countries to treat eligible patients with either of those conditions. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit .
關於CRISPR Therapeutics
自十多年前成立以來，CRISPR Therapeutics已經從一家推進基因編輯領域研究項目的研究階段公司轉變爲一家在2023年慶祝首個CRISPR基礎療法歷史性批准的公司，並在包括血紅蛋白病、腫瘤學、再生醫學、心血管、自身免疫疾病和罕見疾病等廣泛疾病領域中擁有多樣化的產品候選組合。CRISPR Therapeutics在2018年將首個CRISPR/Cas9基因編輯療法推進至臨牀，以研究鐮狀細胞病或依賴輸血的β-地中海貧血的治療，2023年底開始，CASGEVY（exagamglogene autotemcel [exa-cel]）在某些國家獲得批准，用於治療符合條件的患者。諾貝爾獎獲獎的CRISPR科學已徹底改變生物醫藥研究，代表了一種強大的、經過臨牀驗證的方法，具有創造潛在變革性新藥物類別的潛力。爲了加速和擴大其努力，CRISPR Therapeutics與領先公司建立了戰略合作伙伴關係，包括拜耳和福泰製藥。CRISPR Therapeutics AG總部位於瑞士蘇黎世，其全資美國子公司CRISPR Therapeutics, Inc.和研發業務設在馬薩諸塞州波士頓和加利福尼亞州舊金山，同時在英國倫敦設有業務辦事處。欲了解更多信息，請訪問。
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
投資者聯繫人：
蘇珊·金
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com
媒體聯繫人：
瑞秋·艾德斯
+1-617-315-4493
rachel.eides@crisprtx.com
譯文內容由第三人軟體翻譯。
